Marc Cohen, MD, José Diez, MD, Glenn N. Levine, MD, James J. Ferguson III, MD, David A. Morrow, MD, MPH, Sunil V. Rao, MD, James P. Zidar, MD

---

Target Audience: Clinical and Interventional Cardiologists and Nurses who treat patients with cardiovascular disease

---

Learning Objectives: Upon completion of this educational activity, participants should be able to: Describe the latest pharmacologic treatment options for ACS patients, increase guideline adherence to positively affect patient outcomes, provide early and timely intervention which is critical to positive patient outcomes.

---

Faculty Disclosures: All those with control over the content of continuing education programs sponsored by NACCME are expected to disclose whether they do or do not have any real or apparent conflict(s) of interest or other relationships related to the content of their presentation(s). It is not assumed that these relationships will have an adverse impact on presentations; they are simply noted here to fully inform participants.

Dr. Cohen has disclosed that he has received grant/research support from Bayer and Sanofi-Aventis. He is a consultant to Sanofi-Aventis and a member of the speakers’ bureau for BMS, Merck, Sanofi-Aventis and Schering.

Dr. Diez has disclosed that he is a consultant to Sanofi-Aventis.

Dr. Levine declares that he attended one consultants meeting sponsored by The Medicines Company.

Dr. Ferguson has disclosed that he has received research grants from Eisai Pharmaceuticals, Sanofi-Aventis and The Medicines Company. He is a consultant for Astellas Pharmaceuticals, Astra Zeneca, Bristol Myers Squibb, Daiichi-Sankyo, Eisai Pharmaceuticals, Eli Lilly, GSK, Johnson & Johnson, Sanofi-Aventis Shering-Plough, Takeda Pharmaceuticals, The Medicines Company and Therox. He is a member of the speakers’ bureau for Bristol Myers Squibb, Sanofi- Aventis, and Schering-Plough.

Dr. Morrow has disclosed that he has received research grant support from Bristol Myers-Squibb, Daiichi Sankyo, Eli Lilly & Co, Sanofi Aventis, and Schering Plough Research Institute and honoraria for educational presentations from Sanofi Aventis.

Dr. Rao has disclosed that he has received grant/research support from Cordis Corporation, Momenta Pharmaceuticals. He is a consultant and member of the speakers’ bureau for Sanofi-Aventis and The Medicines Company.

Dr. Zidar has disclosed that he has received grant/research support from Abbott Vascular and Cordis. He is a scientific advisor for Abbott Vascular, Cordis and Medtronic.

All those involved in the planning and editing of this educational activity have disclosed that they have no significant financial relationship with any organization that could be perceived as a real or apparent conflict of interest in the context of this educational activity.

---

Commercial Supporter: This activity is supported by an educational grant from Sanofi-Aventis.

---

Conflict of Interest Resolution/Content Validation: In compliance with ACCME Standards for Commercial Support and NACCME’s policy and procedure for resolving conflicts of interest, this continuing medical education activity was reviewed by a member of the NACCME Cardiology Advisory Board in November 2007 for clinical content validity, to insure that the activity’s materials are fair, balanced, and free of bias toward the commercial supporters of the activity, and that activity materials represent a standard of practice within the profession in the U.S. and that any studies cited in the materials upon which recommendations are made are scientifically objective and conform to research principles generally accepted by the scientific community.

---

Sponsor: North American Center for Continuing Medical Education.

---

Release Date: 12-24-07 Expiration Date: 12-24-08

---

Accreditation:

MD/DO: This activity is sponsored by the North American Center for Continuing Medical Education (NACCME). NACCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. NACCME designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. This activity has been planned and produced in accordance with the ACCME Essential Areas and Policies.

Nurses: ANCC: NACCME is an approved provider of continuing nursing education by the Pennsylvania State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. This continuing nursing education activity was approved by the Pennsylvania State Nurses Association for 2 contact hours. Provider #110-3-E-06. Provider approved by the California Board of Registered Nursing, Provider #13255 for 2 contact hours.

---

Off-Label/Unapproved Usage Discussion: This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither NACCME, Eli Lilly, Schering-Plough, The Medicines Company, Daiichi-Sankyo, nor Sanofi Aventis, recommends the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.